GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Gilead Sciences Inc (XSWX:GILD) » Definitions » EV-to-EBITDA

Gilead Sciences (XSWX:GILD) EV-to-EBITDA : 10.04 (As of Apr. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Gilead Sciences EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Gilead Sciences's enterprise value is CHF94,518 Mil. Gilead Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was CHF9,410 Mil. Therefore, Gilead Sciences's EV-to-EBITDA for today is 10.04.

The historical rank and industry rank for Gilead Sciences's EV-to-EBITDA or its related term are showing as below:

XSWX:GILD' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.3   Med: 10.55   Max: 57.02
Current: 9.44

During the past 13 years, the highest EV-to-EBITDA of Gilead Sciences was 57.02. The lowest was 5.30. And the median was 10.55.

XSWX:GILD's EV-to-EBITDA is ranked better than
68.18% of 707 companies
in the Drug Manufacturers industry
Industry Median: 14.03 vs XSWX:GILD: 9.44

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-26), Gilead Sciences's stock price is CHF75.00. Gilead Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was CHF0.000. Therefore, Gilead Sciences's PE Ratio for today is N/A.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Gilead Sciences EV-to-EBITDA Historical Data

The historical data trend for Gilead Sciences's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gilead Sciences EV-to-EBITDA Chart

Gilead Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.93 23.49 9.82 14.22 11.30

Gilead Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.22 11.80 10.77 10.43 11.30

Competitive Comparison of Gilead Sciences's EV-to-EBITDA

For the Drug Manufacturers - General subindustry, Gilead Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's EV-to-EBITDA falls into.



Gilead Sciences EV-to-EBITDA Calculation

Gilead Sciences's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=94517.988/9410.167
=10.04

Gilead Sciences's current Enterprise Value is CHF94,518 Mil.
Gilead Sciences's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF9,410 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Gilead Sciences  (XSWX:GILD) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Gilead Sciences's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=75.00/0.000
=N/A

Gilead Sciences's share price for today is CHF75.00.
Gilead Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Gilead Sciences EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Gilead Sciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Gilead Sciences (XSWX:GILD) Business Description

Address
333 Lakeside Drive, Foster, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.